Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04597580
Other study ID # CTFSp161
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date May 8, 2019
Est. completion date January 31, 2030

Study information

Verified date August 2023
Source The Christie NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with metastatic breast cancer may respond well to treatment and metastases can remain stable for several years. Despite personalised medicine being increasingly used for diagnosis and treatment, follow-up still include radiological response evaluation every 3-4 months, which renders a significant number of 'unnecessary' exams for patients with long-term stable disease. Increasing evidence indicates that tumour markers such as circulating tumour DNA (ctDNA), thymidine kinase 1 (TK1) and cancer antigen 15-3 (CA15-3) may be useful for disease monitoring in the metastatic setting. However, algorithms that accurately define the time-points at which imaging can be foregone or reinstituted when progression is forecast, have not been developed. This study will measure ctDNA, TK1 and CA15-3 at all imaging time-points. The primary aim is to develop an algorithm based on these biomarkers, alone or in combination, that with sufficient specificity and sensitivity can advise whether a scan can be safely admitted at a specific time-point, for patients with MBC receiving first line therapy with AI plus cyclin dependent kinase 4/6 inhibitor (CDK4/6i). Additional samples will be stored such that novel biomarkers can also be tested in future. The cost-effectiveness of using the devised biomarker protocol will be evaluated.


Description:

One hundred patients with estrogen receptor positive (ER+)/ Human epidermal growth factor receptor negative (HER2-) metastatic or locally advanced breast cancer, eligible for 1st line endocrine therapy with AI + CDK4/6i will be included. Patients will receive standard therapy (AI + CDK4/6i) and follow-up will proceed according to local guidelines, namely cross sectional imaging with CT thorax/abdomen/pelvis +/- MRI as required and analysis of CA 15-3, every 3 cycles for the first year and every 3-4 cycles thereafter. Participation in the study will include serial blood sampling for the bespoke study biomarkers. Decisions on progression will be made according to the routine imaging tests and the biomarkers will be subsequently analysed. The investigators hypothesise that the biomarkers ctDNA, TK1 and CA15-3, alone or in combination, will accurately correlate with disease status in patients receiving AI + CDK4/6i for metastatic breast cancer such that routine imaging can be delayed until predefined levels of biomarker progression. Primary aim: To develop a biomarker-based prediction model to be used in patients with metastatic breast cancer, receiving first line therapy with AI and CDK4/6i, that provides the physician with a recommendation whether or not a radiological examination is required, based on the likelihood that the scan will actually show progressive disease. Secondary aims - To define the lead time between rising biomarker and subsequent progression on imaging - To define the clinical utility of the bespoke biomarkers for disease monitoring - The relative value of analysing TK1 "on CDK4/6i treatment" versus "off CDK4/6i treatment" for disease monitoring - To define the economic impact of implementation of the chosen prediction model


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 97
Est. completion date January 31, 2030
Est. primary completion date May 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Advanced breast cancer - ER-positive/HER2-negative - For patients who have had a prior non-breast malignancy within the last 5 years (excluding in situ carcinoma of the cervix and basal cell carcinoma of the skin) biopsy of a metastatic site is required to confirm the diagnosis of metastatic ER+/HER2- breast cancer. - Eligible for 1st line endocrine therapy with an aromatase inhibitor and a CDK4/6 inhibitor - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 - Age = 18 years - Life expectancy > 3 months - Radiologically assessable disease Exclusion Criteria: - Known central nervous system (CNS) metastases, carcinomatous meningitis or leptomeningeal disease unless treated with radiotherapy and symptomatically stable at least 2 weeks after discontinuation of steroids - Concurrent disease(s) or familial, sociological or geographical condition that would, in the investigator's opinion, preclude compliance with study procedures - Any serious medical disorder that would compromise the patient's safety - Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of Informed Consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Sweden Department of Oncology, Sahlgrenska University Hospital Gothenburg
Sweden Department of Oncology, Ryhov Hospital Jönköping
Sweden Department of Oncology, Kalmar Hospital Kalmar
Sweden Department of Oncology, Linköping University Hospital Linköping
Sweden Department of Oncology, Södersjukhuset Stockholm
United Kingdom The Christie NHS Foundation Trust Manchester
United Kingdom Wigan Infirmary, Wrightington, Wigan and Leigh NHS Foundation Trust Wigan

Sponsors (2)

Lead Sponsor Collaborator
The Christie NHS Foundation Trust Sahlgrenska University Hospital, Sweden

Countries where clinical trial is conducted

Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in blood levels of ctDNA, CA15-3 and TK-1 assays from baseline to disease progression ctDNA, CA15-3 and TK-1 assays will be performed at baseline, 2 weeks and at every imaging timepoint to develop a statistical algorithm to predict disease progression taht can be tested prospectively in future studies. 3-5 years
Secondary Best time for TK1 analysis during CDK4/6i treatment ("on treatment" vs "off treatment") The relative value of analysing TK1 "on CDK4/6i treatment" versus "off CDK4/6i treatment" for disease monitoring 3-5 years
Secondary The economic impact of implementation of the chosen prediction model Cost effectiveness analysis of the using the prediction model 3-5 years
See also
  Status Clinical Trial Phase
Withdrawn NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04509596 - DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer Phase 1
Recruiting NCT04122469 - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease N/A
Completed NCT03045653 - Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer Phase 2
Terminated NCT03322215 - HR+/HER2- Advanced Breast Cancer and Endocrine Resistance Phase 2
Active, not recruiting NCT04059484 - Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer Phase 2
Recruiting NCT04368442 - Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
Terminated NCT03709082 - Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Phase 1/Phase 2
Terminated NCT03642990 - NR in Chemo-induced Peripheral Neuropathy Phase 2
Terminated NCT01876251 - A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer Phase 1
Completed NCT04483505 - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Phase 1
Recruiting NCT03086785 - Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer Phase 2
Terminated NCT04197999 - A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Phase 1
Not yet recruiting NCT03638765 - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer Phase 1
Recruiting NCT06100874 - A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN) Phase 2
Completed NCT05609903 - Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
Completed NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. Phase 1
Active, not recruiting NCT03328884 - Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients Phase 2
Recruiting NCT05837533 - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients N/A
Completed NCT05155566 - Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.